Novavax, Inc. (NVAX)
NVAX moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How NVAX actually reacts to news — the realized, point-in-time move the market made, measured across 400 labeled events over the last three years with zero look-ahead.
NVAX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 47% | 399 |
| 30-min | 0.00% | 48% | 399 |
| 60-min | 0.00% | 48% | 400 |
| to close | 0.00% | 49% | 399 |
| Middle 50% of NVAX reactions | -1.16% to +1.28% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 400 |
Half of all Novavax, Inc. news events land between -1.16% and +1.28% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How NVAX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 11 | -0.69% | 27% | -0.62% |
| Analyst downgrades | 10 | -2.15% | 30% | -5.95% |
| Rating reiterations | 39 | +0.28% | 56% | -0.63% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how NVAX ranks against every other measured name →
That’s how NVAX usually reacts — get an email when it moves on news →Email me when NVAX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to NVAX's baseline. Nothing else.
Recent NVAX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Novavax to Participate in September Investor Conferences | Press release | PR Newswire | -1.40% | -0.86% | |
| Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season | Press release | PR Newswire | -0.98% | +0.87% | |
| Form 10-Q NOVAVAX INC For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.66% | -1.28% | |
| Form 8-K NOVAVAX INC For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | -2.66% | -1.28% | |
| Form S-8 NOVAVAX INC | SEC filing · Form S-8 | SEC EDGAR | +1.55% | +2.58% | |
| Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights | Press release | PR Newswire | -2.66% | -1.28% | |
| Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026 | Press release | PR Newswire | -1.08% | +0.14% | |
| Form 8-K NOVAVAX INC For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | +4.77% | +2.16% | |
| Novavax to Participate in 2026 Jefferies Global Healthcare Conference | Press release | PR Newswire | -2.31% | -1.83% | |
| Novavax to Participate in BofA Securities 2026 Health Care Conference | Press release | PR Newswire | +1.18% | +8.48% | |
| Form 10-Q NOVAVAX INC For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +9.35% | |
| Form 8-K NOVAVAX INC For: May 06 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +9.35% | |
| Novavax Reports First Quarter 2026 Financial Results and Operational Highlights | Press release | PR Newswire | +0.00% | +9.35% | |
| Novavax to Report First Quarter 2026 Financial Results on May 6, 2026 | Press release | PR Newswire | +0.13% | -1.06% | |
| Form ARS NOVAVAX INC For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.37% | -0.62% | |
| Form DEF 14A NOVAVAX INC For: Jun 18 | SEC filing · Form DEF | SEC EDGAR | +0.73% | -1.22% | |
| Form DEFA14A NOVAVAX INC | SEC filing · Form DEFA14A | SEC EDGAR | +0.73% | -1.22% | |
| Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development | Press release | PR Newswire | -0.71% | -3.92% | |
| Form 10-K NOVAVAX INC For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +5.44% | +14.77% | |
| Form 8-K NOVAVAX INC For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | +5.44% | +14.77% | |
| Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights | Press release | PR Newswire | +5.44% | +14.77% | |
| Novavax to Participate in Upcoming Investor Conferences | Press release | PR Newswire | -4.80% | -9.06% | |
| Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 | Press release | PR Newswire | -0.63% | +6.40% | |
| Form 8-K NOVAVAX INC For: Jan 15 | SEC filing · Form 8-K | SEC EDGAR | +0.08% | +0.49% | |
| Novavax Announces Entering into a License Agreement with Pfizer | Press release | PR Newswire | +0.08% | +0.49% | |
| Form 8-K NOVAVAX INC For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -1.66% | +6.16% | |
| Novavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference | Press release | PR Newswire | +0.80% | +1.47% | |
| Novavax to Participate in Jefferies London Healthcare Conference | Press release | PR Newswire | +0.61% | -2.57% | |
| Form 10-Q NOVAVAX INC For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.21% | +1.47% | |
| Form 8-K NOVAVAX INC For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | +3.21% | +1.47% | |
| Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights | Press release | PR Newswire | +3.21% | +1.47% | |
| Form 8-K NOVAVAX INC For: Nov 03 | SEC filing · Form 8-K | SEC EDGAR | +1.58% | -1.18% | |
| Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment | Press release | PR Newswire | +1.58% | -1.18% | |
| Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025 | Press release | PR Newswire | +0.54% | +1.57% | |
| Form 8-K NOVAVAX INC For: Oct 17 | SEC filing · Form 8-K | SEC EDGAR | +1.07% | +0.24% | |
| Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy | Press release | PR Newswire | +1.07% | +0.24% | |
| Form 8-K NOVAVAX INC For: Oct 01 | SEC filing · Form 8-K | SEC EDGAR | +2.05% | +1.43% | |
| Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment | Press release | PR Newswire | +2.05% | +1.43% | |
| Novavax Announces Progress on Sanofi Agreement | Press release | PR Newswire | -1.47% | +1.88% | |
| Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment | Press release | PR Newswire | -0.20% | +5.27% | |
| Novavax to Participate in the Cantor Global Healthcare Conference | Press release | PR Newswire | +1.26% | -1.60% | |
| Form 8-K NOVAVAX INC For: Aug 27 | SEC filing · Form 8-K | SEC EDGAR | -1.36% | -2.07% | |
| Novavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S. | Press release | PR Newswire | +0.13% | +1.54% | |
| Form 8-K NOVAVAX INC For: Aug 20 | SEC filing · Form 8-K | SEC EDGAR | -2.89% | -6.03% | |
| Novavax Announces Convertible Debt Refinancing | Press release | PR Newswire | -2.89% | -6.03% | |
| Form 10-Q NOVAVAX INC For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +6.50% | +4.70% | |
| Form 8-K NOVAVAX INC For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +6.50% | +4.70% | |
| Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights | Press release | PR Newswire | +6.50% | +4.70% | |
| Novavax to Report Second Quarter 2025 Financial Results on August 6, 2025 | Press release | PR Newswire | -0.02% | -3.27% | |
| Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study | Press release | PR Newswire | +0.48% | -5.68% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the NVAX section they belong to.
Where else NVAX is measured.
NVAX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| EDGE THERAPEUTICS (EDGE) | 401 | -0.05% | 41% |
| Esperion Therapeutics, Inc. (ESPR) | 401 | 0.00% | 47% |
| AMEDICA CORP COMMON STOCK (AMDA) | 397 | -1.09% | 31% |
| PAIN THERAPEUTICS (PTIE) | 397 | -0.01% | 41% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Novavax, Inc.'s median reaction calculated?
Every labeled NVAX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 400 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of NVAX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does NVAX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.